MIDDLETON FRED A

Form 4

March 05, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB

3235-0287 Number:

January 31, Expires: 2005

OMB APPROVAL

Estimated average burden hours per response... 0.5

5. Relationship of Reporting Person(s) to

Issuer

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

2. Issuer Name and Ticker or Trading

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

Symbol

1(b).

Stock

(Print or Type Responses)

MIDDLETON FRED A

1. Name and Address of Reporting Person *

		Steree	otaxis, Inc. [STXS]	(Check al	ll applicable)
	(First) REOTAXIS, INC. PARK AVENUE	(Montl), 4320 (3/02)	e of Earliest Transaction n/Day/Year) n/2018	X Director Officer (give title below)	10% Owner
	(Street)	4. If A	mendment, Date Original	6. Individual or Joint/	/Group Filing(Check
ST. LOUI	S, MO 63108	Filed(N	Month/Day/Year)	Applicable Line) _X_ Form filed by One Form filed by More Person	Reporting Person than One Reporting
(City)	(State)	(Zip) Ta	able I - Non-Derivative Securities Ac	quired, Disposed of, or	Beneficially Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 03/02/2018	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price X 153,846 A	5. Amount of Securities Owned Beneficially Form Owned Direct Following or Inc Reported (I) Transaction(s) (Instr. 3 and 4) 303,528 D	et (D) (Instr. 4)
Stock	03/02/2010		0.28	303,320 D	
Common Stock				1,107,189 I	Sanderling Venture Partners VI Co-Investment Fund, L.P.
Common				6,358 I	Sanderling VI Limited

Partnership

Edgar Filing: MIDDLETON FRED A - Form 4

Common Stock	5,335	I	Sanderling VI Beteiligungs GmbH & Co. KG
Common Stock	53,275	I	Sanderling IV Biomedical Co-Investment Fund, L.P.
Common Stock	11,097	I	Sanderling V Beteiligungs GmbH & Co. KG
Common Stock	39,716	I	Sanderling V Biomedical Co-Investment Fund, L.P.
Common Stock	11,956	I	Sanderling V Limited Partnership
Common Stock	67,790	I	Sanderling Venture Partners V Co-Investment Fund, L.P.
Common Stock	22,451	I	Sanderling Venture Partners IV Co-Investment Fund

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Se Acquired (A) Disposed of (Instr. 3, 4, and	ecurities or (D)	6. Date Exerc Expiration Da (Month/Day/	ite	7. Title a Underlyi (Instr. 3	ing Sec
	·			Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	A N S

(9-02)

Edgar Filing: MIDDLETON FRED A - Form 4

Common Stock Warrant (right to buy)	\$ 0.7	03/01/2018(1)	D	153,846	09/29/2016	09/29/2021	Common Stock
Common Stock Warrant (right to buy)	\$ 0.28	03/01/2018(1)	A 153,8	846	09/29/2016	09/29/2021	Common Stock
Common Stock Warrant (right to	\$ 0.28	03/02/2018	X	153,846	09/29/2016	09/29/2021	Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships				
1	Director	10% Owner	Officer	Other	
MIDDLETON FRED A C/O STEREOTAXIS, INC. 4320 FOREST PARK AVENUE, SUITE 100 ST. LOUIS, MO 63108	X				

Signatures

buy)

/s/ Karen Witte Duros, Attorney-in-Fact 03/05/2018

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On February 28, 2018, the issuer and certain holders of outstanding warrants issued pursuant to the Stock Purchase Agreement dated September 26, 2016, including the reporting person, entered into an amendment to the warrants. The amendment provided that the exercise price of the warrants would be reduced for a limited period of time, provided that at least \$6 million of warrants was exercised during the limited period. This condition was satisfied on March 1, 2018.
- The transactions reported in the first two lines of Table II above report the amendment of the warrant to temporarily reduce the exercise price from \$0.70 per share to \$0.28 per share. The amendment is reported as the disposition of the old warrant and the acquisition of a new one. The amendment to the warrant was approved by a transaction committee consisting solely of independent directors for purposes of Rules 16b-3(d) and (e).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3